

11-08-06

IFW
SF



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Ben-Sasson et al.
SERIAL NUMBER: 10/501,838 EXAMINER : S. Gudibande
FILING DATE: November 29, 2004 ART UNIT : 1654
FOR: AMINO ACID SEQUENCE CAPABLE OF FACILITATING
PENETRATION ACROSS A BIOLOGICAL BARRIER

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (4 pages), in duplicate;
3. Copies of Cited References: B1-3; C1-C49;
4. Check in the amount of \$180.00 (#23262); and
5. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24348-501 NATL. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,




Ivor R. Elrifi, Reg. No. 39,529
Christina K. Stock, Reg. No. 45,899

Attorney(s) for Applicants
c/o MINTZ, LEVIN
Address all written correspondence to
Customer no.: 30623
Tel: (617) 542-6000

Date: November 6, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



APPLICANTS: Ben-Sasson et al.
SERIAL NUMBER: 10/501,838 EXAMINER : S. Gudibande
FILING DATE: November 29, 2004 ART UNIT : 1654
FOR: AMINO ACID SEQUENCE CAPABLE OF FACILITATING
PENETRATION ACROSS A BIOLOGICAL BARRIER

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311. The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed. By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A5 and U.S. Published Applications A6-A7 are not submitted.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the

APPLICANTS: **Ben-Sasson, et al.**
U.S.S.N.: **10/501,838**

information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 24348-501 NATL.

Respectfully submitted,




Ivor R. Elrifi, Reg. No. 39,529
Christina K. Stock, Reg. No. 45,899
Attorney(s) for Applicants
c/o MINTZ, LEVIN
Address all written correspondence to
Customer no.: 30623
Tel: (617) 542-6000

Date: November 6, 2006

TRA 2213601v.1

Express Mail No.: EV 869858356 US
Date of Deposit: November 6, 2006

Page 1 of 4
Attorney Docket No.: 24348-501 NATL



Please type a plus sign (+) in this box

+

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>Modified Form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>					Application Number	10/501,838		
					Filing Date	November 29, 2004		
					First Named Inventor	Ben-Sasson		
					Group Art Unit	1654		
					Examiner Name	Satyanarayan R. Gudibande		
					Attorney Docket Number	24348-501 NATL		
U.S. PATENT DOCUMENTS								
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate	
	*A1	3,710,795	01/16/73	Higuchi et al.	128	260		
	*A2	4,179,337	12/18/79	Davis et al.	435	181		
	*A3	4,873,316	10/10/89	Meade et al.	530	412		
	*A4	5,262,564	11/16/93	Kun et al.	562	430		
	*A5	5,827,534	10/27/98	Fasano	424	451		
U.S. PUBLISHED APPLICATION DOCUMENTS								
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate	
	*A6	2003/0060438 A1	03/27/03	Henry et al.	514	44		
	*A7	2004/0176476 A1	09/09/04	Gyurik	514	772.6		
FOREIGN PATENT DOCUMENTS								
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		
	B1	EP	0 264 166 A1	INTEGRATED GENETICS, INC.	04/20/88			
	B2	WO	96/05858	WASHINGTON UNIVERSITY; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY	02/29/96			
	B3	WO	03/066859 A2	YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIV. OF JERUSALEM	08/14/03			
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS								
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.						
	C1	Amann, et al., "Tightly regulated tac promoter vectors useful for the expression of unfused and fused proteins in <i>Escherichia coli</i> ", <i>Gene</i> , 69(2):301-315 (1988)						
	C2	Armstrong, W.M., "Cellular mechanisms of ion transport in the small intestine", <i>Physiol. Gastrointest. Tract</i> , 2 nd Ed., Johnson, ed., Raven Press, New York, Chapter 45, pp. 1251-1265 (1987)						
	C3	Baldari et al., "A novel leader peptide which allows efficient secretion of a fragment of human interleukin 1 β in <i>Saccharomyces cerevisiae</i> ", <i>EMBO J.</i> , 6(1):229-234 (1987)						

	C4	Banerji et al., "A lymphocyte-specific cellular enhancer is located downstream of the joining region in immunoglobulin heavy chain genes", <i>Cell</i> , 33:729-740 (1983)
	C5	Bernkop-Schnürch, et al., "The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins", <i>J. Control. Release</i> , 52:1-16 (1998)
	C6	Bolton et al., "The labelling of proteins to high specific radioactivities by conjugation to a ¹²⁵ I-containing acylating agent", <i>Biochem. J.</i> , 133:529-539 (1973)
	C7	Byrne and Ruddle, "Multiplex gene regulation: a two-tiered approach to transgene regulation in transgenic mice", <i>Proc. Natl. Acad. Sci. USA</i> , 86:5473-5477 (1989)
	C8	Calame and Eaton, "Transcriptional controlling elements in the immunoglobulin and T cell receptor loci", <i>Adv. Immunol.</i> , 43:235-275 (1988)
	C9	Camper and Tilghman, "Postnatal repression of the α -fetoprotein gene is enhancer independent", <i>Genes Dev.</i> , 3:537-546 (1989)
	C10	Citi, S., "Protein kinase inhibitors prevent junction dissociation induced by low extracellular calcium in MDCK epithelial cells", <i>J. Cell Biol.</i> , 117(1):169-178 (1992)
	C11	Claude et al., "Fracture faces of zonulae occludentes from 'tight' and 'leaky' epithelia", <i>J. Cell Biol.</i> , 58:390-400 (1973)
	C12	Edlund et al., "Cell-specific expression of the rat insulin gene: evidence for role of two distinct 5' flanking elements", <i>Science</i> , 230:912-916 (1985)
	C13	Encyclopedia of Molecular Biology, "Peptide synthesis", pg. 806 (1994)
	C14	Farquhar et al., "Junctional complexes in various epithelia", <i>J. Cell Biol.</i> , 17:375-412 (1963)
	C15	Fasano et al., "Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions", <i>Proc. Natl. Acad. Sci. USA</i> , 88:5242-5246 (1991)
	C16	Fasano et al., "Modulation of intestinal tight junctions by zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model", <i>J. Clin. Invest.</i> , 99(6):1158-1164 (1997)
	C17	Fiorentini et al., "Clostridium difficile toxin A and its effects on cells", <i>Toxicon</i> , 29(6):543-567 (1991)
	C18	Fox, J., "Developments in parathyroid hormone and related peptides as bone-formation agents", <i>Curr. Opin. Pharmacol.</i> , 2:338-344 (2002)
	C19	Gottesman, S., "Minimizing proteolysis in <i>Escherichia coli</i> : genetic solutions", <i>Methods in Enzymology</i> , in <u>Gene Expression Technology</u> , Volume 185:119-128 (1990)
	C20	Gumbiner, B., "Structure, biochemistry, and assembly of epithelial tight junctions", <i>Am. J. Physiol.</i> , 253:C749-C758 (1987)
	C21	Hecht et al., "Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers", <i>J. Clin. Invest.</i> , 82:1516-1524 (1988)
	C22	Heiskala et al., "The role of claudin superfamily proteins in paracellular transport", <i>Traffic</i> , 2:92-98 (2001)
	C23	Ho et al., "Influence of pluronic F-68 on dissolution and bioavailability characteristics of multiple-layer pellets of nifedipine for controlled release delivery", <i>J. Controlled Rel.</i> , 68:433-440 (2000)
	C24	Inoue et al., "Involvement of tachykinin receptors in oedema formation and plasma extravasation induced by substance P, neurokinin A, and neurokinin B in mouse ear", <i>Inflamm. Res.</i> , 45:316-323 (1996)
	C25	Jackson, L.R., "Drug transport across gastrointestinal epithelia", <i>Physiol. Gastrointest. Tract</i> , 2 nd Ed., Johnson, ed., Raven Press, New York, Chapter 59, pgs. 1597-1621 (1987).

	C26	Peter et al., "Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibitor after activation by factor Xa", <i>Circulation</i> , 101:1158-1164 (2000)
	C27	Kaufman et al., "Translational efficiency of polycistronic mRNAs and their utilization to express heterologous genes in mammalian cells", <i>EMBO J.</i> , 6(1):187-193 (1987)
	C28	Kessel and Gruss, "Murine developmental control genes", <i>Science</i> , 249:374-379 (1990)
	C29	Kristensen et al., "Specificity of insulin and insulin-like growth factor I receptors investigated using chimeric mini-receptors", <i>J. Biol. Chem.</i> , 274(52):37351-37356 (1999)
	C30	Kurjan and Herskowitz, "Structure of a yeast pheromone gene (MFa): a putative α -factor precursor contains four tandem copies of mature α -factor", <i>Cell</i> , 30:933-943 (1982)
	C31	Luckow and Summers, "High level expression of nonfused foreign genes with <i>autographa californica</i> nuclear polyhedrosis virus expression vectors", <i>Virology</i> , 170:31-39 (1989)
	C32	Madara et al., "Effects of cytochalasin D on occluding junctions of intestinal absorptive cells: further evidence that the cytoskeleton may influence paracellular permeability and junctional charge selectivity", <i>J. Cell Biol.</i> , 102(6):2125-2136 (1986)
	C33	Madara, J.L., <i>J. Clin. Invest.</i> , "Loosening tight junctions", 83:1089-1094 (1989)
	C34	Merrifield, R.B., "Solid phase peptide synthesis. I. the synthesis of a tetrapeptide", <i>J. Am. Chem. Soc.</i> , 85:2151-2154 (1963)
	C35	O'Shaughnessy and Connor, "Neurokinin NK ₁ receptors mediate plasma protein extravasation in guinea-pig dura", <i>Eur. J. Pharmacol.</i> , 236:319-321 (1993)
	C36	Pinkert et al., "An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice", <i>Genes Dev.</i> , 1:268-277 (1987)
	C37	Queen and Baltimore, "Immunoglobulin gene transcription is activated by downstream sequence elements", <i>Cell</i> , 33:741-748 (1983)
	C38	Schultz et al., "Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus", <i>Gene</i> , 54:113-123 (1987)
	C39	Seed, B., "An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2", <i>Nature</i> , 329:840-842 (1987)
	C40	Smith et al., "Production of human beta interferon in insect cells infected with a baculovirus expression vector", <i>Mol. Cell. Biol.</i> , 3(12):2156-2165 (1983)
	C41	Smith et al., "Single-step purification of polypeptides expressed in <i>Escherichia coli</i> as fusion with glutathione S-transferase", <i>Gene</i> , 67(1):31-40 (1988)
	C42	Stevenson et al., "Zonulae occludentes in junctional complex-enriched fractions from mouse liver: preliminary morphological and biochemical characterization", <i>J. Cell Biol.</i> , 98(4):1209-1221 (1984)
	C43	Studier, et al., <i>Gene Expression Technology: Methods in Enzymology</i> , Academic Press, San Diego, Calif., 185:60-89 (1990).
	C44	Van Schilfgaarde et al., "Cloning of genes of nontypeable <i>haemophilus influenzae</i> involved in penetration between human lung epithelial cells", <i>Infect. Immun.</i> , 68(8):4616-4623 (2000)
	C45	Wada et al., "Codon usage tabulated from the GenBank genetic sequence data", <i>Nucl. Acids Res.</i> , 20(suppl.):2111-2118 (1992)
	C46	Wang et al., "Increasing epithelial junction permeability enhances gene transfer to airway epithelia in vivo", <i>Am. J. Respir. Cell Mol. Biol.</i> , 22:129-138 (2000)

Express Mail No.: EV 869858356 US
Date of Deposit: November 6, 2006

Page 4 of 4
Attorney Docket No.: 24348-501 NATL

	C47	Weintraub et al., "Anti-sense RNA as a molecular tool for genetic analysis", <i>Trends Gen.</i> , 1:22-25 (1985)
	C48	Winoto and Baltimore, "A novel, inducible and T cell-specific enhancer located at the 3' end of the T cell receptor α locus", <i>EMBO J.</i> , 8(3):729-733 (1989)
	C49	Yowell et al., "Novel effects with polyethylene glycol modified pharmaceuticals", <i>Cancer Treat. Rev.</i> , 28(Suppl. A):3-6 (2002)

* By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A5 and of the U.S. Published Applications A6-A7 are not submitted.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TRA 2211875v.1